中珠医疗(600568) - 2025 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a net profit attributable to shareholders for 2025 to be between -100 million and -150 million yuan[3]. - The expected net profit attributable to shareholders after deducting non-recurring gains and losses for 2025 is projected to be between -110 million and -160 million yuan[5]. - The estimated net profit for 2025 represents a reduction in losses compared to the previous year[5]. Previous Year Financial Results - In 2024, the total profit was -627.30 million yuan, with a net profit attributable to shareholders of -620.22 million yuan[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses in 2024 was -623.87 million yuan[7]. - The company reported a loss per share of -0.3148 yuan for the previous year[8]. Reasons for Expected Losses - The primary reasons for the expected losses include asset impairment losses due to declining real estate prices and significant bad debt provisions from joint ventures[9]. - The Beijing Loyal Oncology Hospital project is incurring losses and is undergoing court-ordered vacating[10]. Financial Data and Auditing - The financial data provided is preliminary and has not been audited by registered accountants[11]. - Investors are advised to exercise caution as the final audited financial data will be disclosed in the official 2025 annual report[12].